Tigecycline (TIG) is a Food and Drug Administration (FDA)- approved antibiotic that has recently demonstrated its anti-cancer properties in diverse tumour types. This review will discuss current research findings and future directions pertaining to the use of TIG in mitigating acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), gastric cancer, hepatocellular carcinoma (HCC), breast cancer, melanoma, cervical squamous cell carcinoma (CSCC), and glioblastoma (GM). TIG exerts its

more »

... apeutic effects via inhibition of mitochondrial functionality, interference of various signal transduction pathways, and acting synergistically with preexisting chemotherapy drugs, all of which contribute to cell death. In comparison to conventional treatments such as chemotherapy, TIG may result in less severe and reduced side effects; this may be attributed to its selectivity and non-invasiveness. Upon evaluation of TIG's efficacy in targeting multiple cancer-types, future efforts should aim to validate findings through human trials, broadening the scope of cancers targeted, establishing novel TIG derivatives, and assessing its performance when used in combination with other treatments.